• Odyssey Therapeutics director Jeffrey M. Leiden reported purchase of 5,000 common shares at USD 20, lifting direct holdings to 270,198 shares.
• Racing Beach Ventures LLC, where Leiden is managing member, reported 31,644 Odyssey common shares held indirectly following preferred-stock conversions and warrant exercise tied to IPO-related restructuring.
• Leiden also reported receipt of a stock option for 626,220 shares with an exercise price of USD 18.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-217607), on May 11, 2026, and is solely responsible for the information contained therein.